BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents


11/15/2011 10:55:52 AM

HOBOKEN, N.J. and PHILADELPHIA, Nov. 15, 2011 /PRNewswire/ -- Niiki Pharma Inc. presented the results of preclinical combination studies of its lead product, NKP-1339, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in San Francisco, CA, November 12-16, 2011.

The data were presented as a poster, titled "NKP-1339 synergistic activity in both in vitro and in vivo preclinical models highlights the therapeutic opportunity for NKP-1339 combination trials with a broad range of anti-tumor agents."

Data summary:

  • In vitro combination studies were performed in breast, colon, lung, gastric, prostate, pancreatic and liver tumor cell lines. NKP-1339 was tested in combination with cisplatin, oxaliplatin, 5-FU, docetaxel, doxorubicin, gemcitabine, erlotinib or sorafenib as appropriate for each tumor cell type. Synergistic cytotoxicity was seen with all combinations tested.
  • In vivo gastric carcinoma xenograft model was tested with NKP-1339 in combination with cisplatin. The combination showed significant (P<0.05) tumor growth delay and extended survival when compared to the single agent activity for either compound.

The broad synergism of NKP-1339 across the tested anti-neoplastic agents is consistent with its proposed mechanism of action through inhibition of the GRP78 pathway.

"The synergy we have demonstrated in both in vitro and in vivo settings suggests that NKP-1339 will be effective in combination with these anti-cancer agents in the clinical setting. The favorable efficacy and safety profile observed to date in our ongoing single agent NKP-1339 Phase I trial warrants its investigation in combination studies for our next round of clinical trials," noted Angela Ogden MD, Chief Medical Officer at Niiki Pharma.

About NKP-1339

NKP-1339 is a first-in-class small molecule anti-cancer compound. NKP-1339 down-regulates the GRP78 pathway, a key regulator of mis-folded protein processing and a tumor survival factor. Up-regulation of GRP78 is associated with intrinsic and chemotherapy-induced resistance in many tumor types. In preclinical studies, single agent NKP-1339 has demonstrated activity against multiple tumor types, including those resistant to other anti-cancer agents.

NKP-1339 was discovered by Professor Bernhard K. Keppler, Dean of the Faculty of Chemistry at University of Vienna, Austria and President of Austrian Association of University Professors.

About Niiki Pharma Inc.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics.

Links


Niiki Pharma Inc.

www.niikipharma.com

Professor Bernhard K. Keppler, University of Vienna

http://anorg-chemie.univie.ac.at



SOURCE Niiki Pharma Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES